Exenatide implant therapy in diabetes.
J Pak Med Assoc. 2018 Oct;68(10):1538-1540
Authors: Kalra S, Saboo B
This review describes a recent advance in diabetes pharmacotherapeutics and drug delivery. ITCA 650 is an implantable device which delivers sustained and stable concentrations of the glucagon-like peptide 1 receptor agonist exenatide, when inserted subcutaneously. The article discusses the pharmacodynamics and pharmacokinetics of ITCA 650, and suggests how it’s benefits can be utilized in clinical practice. It lists the advantages and limitations of the device, and shares tips for its rational use in type 2 diabetes care.
PMID: 30317359 [PubMed – in process]